Measuring kinetics and metastatic propensity of CTCs by blood exchange between mice

Biology Biology
Cancer Cancer
Genomics Genomics
Immunology Immunology
Physics Physics
R&D R&D
Technology Technology
Alex K. Shalek Alex K. Shalek
Nolawit Mulugeta Nolawit Mulugeta

Hamza et al.▾ Hamza, B.*, Miller, A.B.*, Meier, L., Stockslager, M., Ng, S.R., King, E.M., Lin, L., DeGouveia, K.L., Mulugeta, N., Calistri, N.L., Strouf, H., Bray, C., Rodriguez, F., Freed-Pastor, W.A., Chin, C.R., Jaramillo, G.C., Burger, M.L., Weinberg, R.A., Shalek, A.K., Jacks, T., Manalis, S.R.

Nature Communications

October, 2021

Abstract

Existing preclinical methods for acquiring dissemination kinetics of rare circulating tumor cells (CTCs) en route to forming metastases have not been capable of providing a direct measure of CTC intravasation rate and subsequent half-life in the circulation. Here, we demonstrate an approach for measuring endogenous CTC kinetics by continuously exchanging CTC-containing blood over several hours between un-anesthetized, tumor-bearing mice and healthy, tumor-free counterparts. By tracking CTC transfer rates, we extrapolated half-life times in the circulation of between 40 and 260 s and intravasation rates between 60 and 107,000 CTCs/hour in mouse models of small-cell lung cancer (SCLC), pancreatic ductal adenocarcinoma (PDAC), and non-small cell lung cancer (NSCLC). Additionally, direct transfer of only 1−2% of daily-shed CTCs using our blood-exchange technique from late-stage, SCLC-bearing mice generated macrometastases in healthy recipient mice. We envision that our technique will help further elucidate the role of CTCs and the rate-limiting steps in metastasis.